Intervention not reported
TXA given intravenously at a total dose of 1 g pre‐incision and intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin) Comparator…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
TXA given intravenously at a total dose of 1 g intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin) Comparator…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
TXA given intravenously at a total dose of 2 g pre‐incision · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
2 participants
Moderate
Intervention not reported
TXA given intravenously and intra‐articularly at a total dose of 2 g intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
2 participants
Moderate
Intervention not reported
TXA given intravenously and orally at a total dose of greater than 3 g pre‐incision and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
3 participants
Low
Intervention not reported
TXA given intravenously at a total dose of 1 g pre‐incision and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
TXA given intravenously and intra‐articularly at a total dose of greater than 3 g pre‐incision, intraoperatively and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
3 participants
Low
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid may leads to lower risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction (0 to 30 days) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of myocardial infarction (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Stroke · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of cerebrovascular accident/stroke (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of suspected serious drug reactions (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction (0 to 30 days) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of myocardial infarction (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Stroke · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of cerebrovascular accident/stroke (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of suspected serious drug reactions (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of suspected serious drug reactions (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review